DSIJ Mindshare

This chemicals company signs a MoU with 3xper Innoventure Ltd, a technological collaboration for new age pharma molecules!
Siddharth Mane
/ Categories: Trending, Mindshare

This chemicals company signs a MoU with 3xper Innoventure Ltd, a technological collaboration for new age pharma molecules!

The company has delivered returns of 63 per cent over the past year and returns of 102 per cent from the date of its listing in March 2021.

Anupam Rasayan India Ltd (ARIL) is a leading Indian company specializing in custom synthesis (CSM) and the manufacturing of specialty chemicals. Established in 1984, the company operates in two main sectors: Life science-related specialty chemicals, which include products for agrochemicals, personal care, and pharmaceuticals, and other specialty chemicals like specialty pigments, dyes, and polymer additives. ARIL serves a wide range of customers from India and around the world, with over 71 domestic and international clients, including 27 multinational companies.

The company operates six manufacturing facilities in Gujarat, India, with four located in Sachin, Surat, and two in Jhaghadia, Bharuch, boasting a combined installed capacity of approximately 27,000 MT as of March 31, 2023. ARIL specializes in multistep synthesis and complex chemical reaction technologies, catering to a diverse customer base in India and globally.

DSIJ offers a service 'Mid Bridge' with recommendations for Mid-Cap stocks based on research and analysis to help subscribers make informed investment decisions. If this interests you, then do download the service details pdf here

Anupam Rasayan, a prominent manufacturer of custom synthesis and specialty chemicals in India has entered into a Memorandum of Understanding (MoU) with 3xper Innoventure Limited. 3xper Innoventure Limited is a subsidiary of Tube Investments of India Limited, a renowned business conglomerate in India. The collaboration aims to supply specific and designated new-age pharmaceutical molecules. These identified products for Active Pharmaceutical Ingredients (API) will be developed utilizing the CRAMS and CDMO models.

The company has delivered returns of 63 per cent over the past year and returns of 102 per cent from the date of its listing in March 2021. Additionally, the company has a ROCE of 10.6 per cent and a ROE of 8.25 per cent.

On Monday, shares of the company plunged by 2.49 per cent to trade at Rs 1004.10.

Investors should keep a close eye on this buzzing stock.

Previous Article 260 per cent returns in just 3 years; shares of this multibagger NBFC surge by 20 per cent reaching its upper circuit limit!
Next Article Revving to new heights: multibagger commercial vehicles stock hits 52-week high with impressive June 2023 sales!
Print
15111 Rate this article:
4.0
Please login or register to post comments.
DALAL STREET INVESTMENT JOURNAL - DEMOCRATIZING WEALTH CREATION

Principal Officer: Mr. Shashikant Singh,
Email: principalofficer@dsij.in
Tel: (+91)-20-66663800

Compliance Officer: Mr. Rajesh Padode
Email: complianceofficer@dsij.in
Tel: (+91)-20-66663800

Grievance Officer: Mr. Rajesh Padode
Email: service@dsij.in
Tel: (+91)-20-66663800

Corresponding SEBI regional/local office address- SEBI Bhavan BKC, Plot No.C4-A, 'G' Block, Bandra-Kurla Complex, Bandra (East), Mumbai - 400051, Maharashtra.
Tel: +91-22-26449000 / 40459000 | Fax : +91-22-26449019-22 / 40459019-22 | E-mail : sebi@sebi.gov.in | Toll Free Investor Helpline: 1800 22 7575 | SEBI SCORES | SMARTODR